in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharma/fine chemicals roundup—24 June 2014
11:49 AM MDT | June 24, 2014 | Deepti Ramesh
FDA issues warning letters to API plants in China and India FDA issued separate warning letters earlier this month to the active pharmaceutical ingredient (API) manufacturing facilities of Tianjin Zhongan Pharmaceutical (Tianjin, China) and Apotex (Toronto) located at Tianjin; and Bangalore, India, respectively, for violating cGMP. The warning letters were published on the FDA Web site last week. FDA issued an import alert against the Bangalore facility in April. FDA has conducted a detailed review of Apotex's responses since the inspection, but the company lacks...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee